Formerly RedShift Systems, RedShiftBio is a provider of innovative analytical instrumentation for the research, development and manufacture of protein therapeutic drugs. The company has developed a powerful new analytical technique, Microfluidic Modulation Spectroscopy (MMS) that enables direct probing of the biophysical structure of proteins. The patented MMS technology provides comprehensive secondary structure information across five key measurements, in a single automated analysis, replacing the requirement to run samples on multiple instruments.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/11/13 | $3,000,000 | Series B |
Technology Venture Partners | undisclosed |
| 01/29/20 | $18,000,000 | Series D |
Waters Corporation | undisclosed |
